Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study

Brain

Volumn 137, Issue 10, 2014, Pages 2743-2758

  Nombela, Cristina ^a   Rowe, James B ^b,c,d   Winder Rhodes, Sophie E ^a   Hampshire, Adam ^e   Owen, Adrian M ^f   Breen, David P ^a   Duncan, Gordon W ^g   Khoo, Tien K ^h   Yarnall, Alison J ^g   Firbank, Michael J ^g   Chinnery, Patrick F ^g   Robbins, Trevor W ^d   O'Brien, John T ^b   Brooks, David J ^e,i   Burn, David J ^g   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h GRIFFITH UNIVERSITY   (Australia)

ⁱ AARHUS UNIVERSITY   (Denmark)

Author keywords

Cognition; Functional MRI; Genetics; Parkinson's disease

Indexed keywords

APOLIPOPROTEIN E; CATECHOL METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; TAU PROTEIN;

AGED; ARTICLE; BRAIN; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; DEPTH PERCEPTION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETICS; HUMAN; IMAGE PROCESSING; IMAGINATION; LONGITUDINAL STUDY; MALE; MEMORY; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR PERFORMANCE; ROTATION;

COGNITION; FUNCTIONAL MRI; GENETICS; PARKINSON'S DISEASE;

AGED; APOLIPOPROTEINS E; BRAIN; CATECHOL O-METHYLTRANSFERASE; COGNITION; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGINATION; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; ROTATION; SPACE PERCEPTION; TAU PROTEINS;

EID: 84907995146     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu201     Document Type: Article

References (97)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92.
2. Aarsland D, Bronnick K, Fladby T. Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep 2011; 11: 371-8.
3. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol 2010; 20: 633-9.
4. Amick MM, Schendan HE, Ganis G, Cronin-Golomb A. Frontostriatal circuits are necessary for visuomotor transformation: mental rotation in Parkinson's disease. Neuropsychologia 2006; 44: 339-49.
5. Baker SC, Rogers RD, Owen AM, Frith CD, Dolan RJ, Frackowiak RS, et al. Neural systems engaged by planning: a PET study of the Tower of London task. Neuropsychologia 1996; 34: 515-26.
6. Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D. Cognitive impairment in nondemented Parkinson's disease. Mov Disord 2011; 26: 2483-95.
7. Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968; 6: 53-60.
8. Beyer MK, Bronnick KS, Hwang KS, Bergsland N, Tysnes OB, Larsen JP, et al. Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. J Neurol Neurosurg Psychiatry 2013; 84: 23-8.
9. Bookheimer S, Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol 2009; 5: 343-62.
10. Bor D, Duncan J, Lee AC, Parr A, Owen AM. Frontal lobe involvement in spatial span: converging studies of normal and impaired function. Neuropsychologia 2006; 44: 229-37.
11. Bronnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP. Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. Neuropsychology 2011; 25: 114-24.
12. Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, et al. Neuropsychological profile of Parkin mutation carriers with and without Parkinson Disease: the CORE-PD Study. J Int Neuropsychol Soc 2011; 17: 91-100.
13. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807-21.
14. Chung SJ, Armasu SM, Biernacka JM, Anderson KJ, Lesnick TG, Rider DN, et al. Genomic determinants of motor and cognitive outcomes in Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 881-6.
15. Cohen MS, Kosslyn SM, Breiter HC, DiGirolamo GJ, Thompson WL, Anderson AK, et al. Changes in cortical activity during mental rotation. A mapping study using functional MRI. Brain 1996; 119 (Pt 1): 89-100.
16. Cools R, D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 2011; 69: e113-25.
17. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125: 584-94.
18. Corballis MC. Mental rotation and the right hemisphere. Brain Lang 1997; 57: 100-21.
19. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
20. Cronin-Golomb A, Braun AE. Visuospatial dysfunction and problem solving in Parkinson's disease. Neuropsychology 1997; 11: 44-52.
21. Crucian GP, Barrett AM, Burks DW, Riestra AR, Roth HL, Schwartz RL, et al. Mental object rotation in Parkinson's disease. J Int Neuropsychol Soc 2003; 9: 1078-87.
22. Davidson PS, Cook SP, McGhan L, Bouchard T, Camicioli R. Source memory in normal aging and Parkinson's disease. J Neuropsychol 2013; 7: 179-92.
23. de Frias CM, Annerbrink K, Westberg L, Eriksson E, Adolfsson R, Nilsson LG. Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. J Cogn Neurosci 2005; 17: 1018-25.
24. Domenger D, Dea D, Theroux L, Moquin L, Gratton A, Poirier J. The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain. Exp Neurol 2012; 233: 513-22.
25. Dove A, Brett M, Cusack R, Owen AM. Dissociable contributions of the mid-ventrolateral frontal cortex and the medial temporal lobe system to human memory. Neuroimage 2006; 31: 1790-801.
26. Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012; 11: 679-87.
27. Elgh E, Domellof M, Linder J, Edstrom M, Stenlund H, Forsgren L. Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 2009; 16: 1278-84.
28. Ezquerra M, Campdelacreu J, Gaig C, Compta Y, Muñoz E, Martí MJ, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. Neurosci Lett 2008; 448: 20-3.
29. Fallon SJ, Williams-Gray CH, Barker RA, Owen AM, Hampshire A. Prefrontal dopamine levels determine the balance between cognitive stability and flexibility. Cereb Cortex 2013; 23: 361-9.
30. Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB. A large study reveals no association between APOE and Parkinson's disease. Neurobiol Dis 2012; 46: 389-92.
31. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
32. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004a; 127: 550-60.
33. Foltynie T, Goldberg TE, Lewis SG, Blackwell AD, Kolachana BS, Weinberger DR, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004b; 19: 885-91.
34. Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord 2008; 23: 2398-403.
35. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci 2004; 8: 325-35.
36. Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27: 965-73.
37. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80: 85-91.
38. Goodglass H, Gleason JB, Bernholtz NA, Hyde MR. Some linguistic structures in the speech of a Broca's aphasic. Cortex 1972; 8: 191-212.
39. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62: 145-53.
40. Gowers WR. A manual of diseases of the nervous system. Philadelphia: Blakiston; 1893.
41. Hampshire A, Highfield RR, Parkin BL, Owen AM. Fractionating human intelligence. Neuron 2012; 76: 1225-37.
42. Hampshire A, MacDonald A, Owen AM. Hypoconnectivity and hyperfrontality in retired American football players. Sci Rep 2013; 3: 2972.
43. Harris IM, Egan GF, Sonkkila C, Tochon-Danguy HJ, Paxinos G, Watson JD. Selective right parietal lobe activation during mental rotation: a parametric PET study. Brain 2000; 123 (Pt 1): 65-73.
44. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
45. Hoogland J, de Bie RM, Williams-Gray CH, Muslimovic D, Schmand B, Post B. Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. Mov Disord 2010; 25: 2550-4.
46. Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 2006; 63: 189-93.
47. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70.
48. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587-98.
49. Jacobs HI, Van Boxtel MP, Heinecke A, Gronenschild EH, Backes WH, Ramakers IH, et al. Functional integration of parietal lobe activity in early Alzheimer disease. Neurology 2012; 78: 352-60.
50. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21: 1343-9.
51. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9: 1200-13.
52. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis 2013; 11: 79-92.
53. Lee AC, Harris JP, Calvert JE. Impairments of mental rotation in Parkinson's disease. Neuropsychologia 1998; 36: 109-14.
54. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003; 23: 6351-6.
55. Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 2004; 62: 2005-9.
56. Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012; 27: 512-8.
57. Multhammer M, Michels A, Zintl M, Mendoza MC, Klunemann HH. A large ApoE epsilon4/epsilon4 homozygous cohort reveals no association with Parkinson's disease. Acta Neurol Belg 2014; 114: 25-31.
58. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-45.
59. Nagano-Saito A, Habak C, Mejia-Constain B, Degroot C, Monetta L, Jubault T, et al. Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson's disease. Neurobiol Aging 2014; 35: 223-31.
60. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-9.
61. Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex 1978; 14: 234-44.
62. Owen A. Working memory in dorsolateral frontal cortex. Trends Cogn Sci 1998; 2: 239.
63. Owen AM, Doyon J, Petrides M, Evans AC. Planning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci 1996; 8: 353-64.
64. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992; 115 (Pt 6): 1727-51.
65. Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW. Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 1995; 33: 1-24.
66. Owen AM, Stern CE, Look RB, Tracey I, Rosen BR, Petrides M. Functional organization of spatial and nonspatial working memory processing within the human lateral frontal cortex. Proc Natl Acad Sci USA 1998; 95: 7721-6.
67. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian Park West study. JAMA Neurol 2013; 70: 580-6.
68. Peplonska B, Safranow K, Gaweda-Walerych K, Maruszak A, Czyzewski K, Rudzinska M, et al. TOMM40 and APOE common genetic variants are not Parkinson's disease risk factors. Neurobiol Aging 2013; 34: 2078-2.
69. Pereira JB, Junque C, Bartres-Faz D, Ramirez-Ruiz B, Marti MJ, Tolosa E. Regional vulnerability of hippocampal subfields and memory deficits in Parkinson's disease. Hippocampus 2013; 23: 720-8.
70. Perfetti B, Varanese S, Mercuri P, Mancino E, Saggino A, Onofrj M. Behavioural assessment of dysexecutive syndrome in Parkinson's disease without dementia: a comparison with other clinical executive tasks. Parkinsonism Relat Disord 2010; 16: 46-50.
71. Poldrack RA. Region of interest analysis for fMRI. Soc Cogn Affect Neurosci 2007; 2: 67-70.
72. Price CJ, Friston KJ. Scanning patients with tasks they can perform. Hum Brain Mapp 1999; 8: 102-8.
73. Pulkes T, Papsing C, Mahasirimongkol S, Busabaratana M, Kulkantrakorn K, Tiamkao S. Association between apolipoprotein E genotypes and Parkinson's disease. J Clin Neurosci 2011; 18: 1333-5.
74. Rowe JB, Owen AM, Johnsrude IS, Passingham RE. Imaging the mental components of a planning task. Neuropsychologia 2001; 39: 315-27.
75. Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, et al. Parkinson's disease and dopaminergic therapy-differential effects on movement, reward and cognition. Brain 2008; 131: 2094-105.
76. Rowe JB, Hughes L, Williams-Gray CH, Bishop S, Fallon S, Barker RA, et al. The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. Neurobiol Aging 2010; 31: 1064-8.
77. Rowe JB, Toni I, Josephs O, Frackowiak RS, Passingham RE. The prefrontal cortex: response selection or maintenance within working memory? Science 2000; 288: 1656-60.
78. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 1988; 111 (Pt 3): 695-718.
79. Selemon LD, Goldman-Rakic PS. Common cortical and subcortical targets of the dorsolateral prefrontal and posterior parietal cortices in the rhesus monkey: evidence for a distributed neural network subserving spatially guided behavior. J Neurosci 1988; 8: 4049-68.
80. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 1982; 298: 199-209.
81. Starr JM, Fox H, Harris SE, Deary IJ, Whalley LJ. COMT genotype and cognitive ability: a longitudinal aging study. Neurosci Lett 2007; 21: 57-61.
82. Stokes PR, Rhodes RA, Grasby PM, Mehta MA. The effects of the COMT Val108/158Met polymorphism on BOLD activation during working memory, planning, and response inhibition: a role for the posterior cingulate cortex? Neuropsychopharmacology 2011; 36: 763-71.
83. Taylor JM, Main BS, Crack PJ. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem Int 2013; 62: 803-19.
84. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-53.
85. Wakabayashi K, Kakita A, Hayashi S, Okuizumi K, Onodera O, Tanaka H, et al. Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol 1998; 95: 450-4.
86. Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol 2004; 17: 195-200.
87. Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, Duda JE, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011; 68: 1562-8.
88. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009a; 132: 2958-69.
89. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007a; 130: 1787-98.
90. Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 2007b; 27: 4832-8.
91. Williams-Gray CH, Hampshire A, Barker RA, Owen AM. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain 2008; 131: 397-408.
92. Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 2009b; 256: 493-8.
93. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013; 84: 1258-64.
94. Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013; 136: 392-9.
95. Wu K, O'Keeffe D, Politis M, O'Keeffe GC, Robbins TW, Bose SK, et al. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain 2012; 135: 2449-57.
96. Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014; 82: 308-16.
97. Zacks JM. Neuroimaging studies of mental rotation: a meta-analysis and review. J Cogn Neurosci 2008; 20: 1-19.